A PAN-USR TB Multi-Center Trial

Tuberculosis (TB) remains a major public health issue and one of the top ten causes of death from a single infectious disease worldwide. China is among the countries with the highest TB burden, ranking third globally for total TB cases and second for drug-resistant TB cases. PAN-TB is an innovative concept in TB treatment, aiming to develop a universal regimen effective for all forms of active TB, including both drug-susceptible and drug-resistant strains. The primary goal of the PAN-TB regimen is to simplify the treatment process, reduce costs, and improve treatment success rates. The ideal Target Regimen Profile (TRP) for PAN-TB includes superior efficacy compared to standard treatment for non-drug-resistant TB, a reduced treatment duration from the current 4-6 months to 2-3 months, and improved safety and tolerability. This project aims to explore a new ultra-short-course treatment regimen for both drug-sensitive (DS-TB) and drug-resistant TB (MDR/RR-TB), which aligns with the latest trends in TB treatment both domestically and internationally. The regimen also has significant practical implications for enhancing treatment efficacy and reducing patient burden. Furthermore, the study will explore the identification of new biomarkers closely linked to treatment outcomes over the course of full-cycle therapy.

NCT Number	NCT06905522
Lead Sponsor	Shenzhen Third People's Hospital Collaborators: First Affiliated Hospital of Zhejiang University, Beijing Chest Hospital, Capital Medical University, Shenyang Tenth People's Hospital, The Sixth People's Hospital of the Xinjiang Uygur Autonomous Region, The Fourth Hospital of Inner Mongolia Autonomous Region, Guizhou Aerospace Hospital
Conditions	Pulmonary Tuberculosis
Enrollment	610 participants
Start Date	2025-06-18
Primary Completion	2029-01 (estimated)
Study Completion	2029-12 (estimated)
Updated on ClinicalTrials.gov	2025-12-01